AKT1 and hepatocellular carcinoma: In hepatocellular carcinoma (HCC) CD73 was shown to contribute to resistance to Lenvatinib, a VEGF inhibitor, through AKT overactivity which resulted in increased SOX9 expression and stemness of HCC cells (13).